Holen Sie sich die Stockscreener-App
2.85
3.39%
-0.10
Handel nachbörslich:
2.89
0.04
+1.40%
Schlusskurs vom Vortag:
$2.95
Offen:
$2.99
24-Stunden-Volumen:
2.57M
Relative Volume:
0.73
Marktkapitalisierung:
$755.66M
Einnahmen:
$194.75M
Nettoeinkommen (Verlust:
$-51.26M
KGV:
-10.18
EPS:
-0.28
Netto-Cashflow:
$-23.38M
1W Leistung:
+6.34%
1M Leistung:
-8.95%
6M Leistung:
+69.64%
1J Leistung:
+115.91%
1-Tages-Spanne:
$2.83
$3.02
1-Wochen-Bereich:
$2.66
$3.02
52-Wochen-Spanne:
$1.255
$4.0787
Akebia Therapeutics Inc Stock (AKBA) Company Profile
Firmenname
Akebia Therapeutics Inc
Sektor
Telefon
617-871-2098
Adresse
245 FIRST STREET, CAMBRIDGE, MA
Vergleichen Sie AKBA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
AKBA
Akebia Therapeutics Inc
|
2.85 | 782.18M | 194.75M | -51.26M | -23.38M | -0.28 |
|
ZTS
Zoetis Inc
|
143.49 | 63.27B | 9.39B | 2.62B | 2.22B | 5.8121 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.31 | 45.67B | 29.96B | 957.25M | 4.77B | 0.2956 |
|
HLN
Haleon Plc Adr
|
9.04 | 39.27B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
20.21 | 23.02B | 16.70B | -157.13M | 1.19B | -0.1446 |
|
UTHR
United Therapeutics Corp
|
448.93 | 20.66B | 3.08B | 1.24B | 1.07B | 25.61 |
Akebia Therapeutics Inc Stock (AKBA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-06-04 | Fortgesetzt | H.C. Wainwright | Buy |
| 2025-04-28 | Eingeleitet | Leerink Partners | Outperform |
| 2025-04-01 | Eingeleitet | Jefferies | Buy |
| 2023-11-29 | Fortgesetzt | BTIG Research | Buy |
| 2023-08-28 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2023-05-31 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2022-03-31 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2022-03-31 | Herabstufung | Mizuho | Buy → Neutral |
| 2022-03-31 | Herabstufung | Needham | Buy → Hold |
| 2022-03-31 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2021-03-08 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2021-01-29 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2019-11-14 | Bestätigt | Needham | Buy |
| 2019-08-06 | Bestätigt | H.C. Wainwright | Buy |
| 2019-07-11 | Bestätigt | H.C. Wainwright | Buy |
| 2019-05-02 | Eingeleitet | JP Morgan | Overweight |
| 2019-03-20 | Eingeleitet | Citigroup | Neutral |
| 2018-09-07 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2018-08-10 | Bestätigt | Needham | Buy |
| 2018-06-06 | Bestätigt | H.C. Wainwright | Buy |
| 2017-12-19 | Eingeleitet | Piper Jaffray | Overweight |
| 2017-12-07 | Eingeleitet | BTIG Research | Buy |
| 2017-09-15 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2017-07-10 | Bestätigt | H.C. Wainwright | Buy |
| 2017-04-27 | Bestätigt | H.C. Wainwright | Buy |
| 2017-04-27 | Bestätigt | Needham | Buy |
| 2016-12-27 | Bestätigt | H.C. Wainwright | Buy |
| 2016-12-20 | Bestätigt | JMP Securities | Mkt Outperform |
| 2016-11-15 | Eingeleitet | Aegis Capital | Buy |
| 2016-09-29 | Eingeleitet | Brean Capital | Buy |
| 2016-03-16 | Bestätigt | Needham | Buy |
| 2016-01-21 | Eingeleitet | Credit Suisse | Neutral |
Alle ansehen
Akebia Therapeutics Inc Aktie (AKBA) Neueste Nachrichten
Weiss Ratings Reiterates Sell (D-) Rating for Akebia Therapeutics (NASDAQ:AKBA) - MarketBeat
Is Intellia Therapeutics (NTLA) Outperforming Other Medical Stocks This Year? - Yahoo Finance
Akebia Therapeutics Achieves Multibagger Status with 123.31% Stock Increase Over Past Year - Markets Mojo
Akebia Therapeutics, Inc.'s (NASDAQ:AKBA) Profit Outlook - simplywall.st
What drives Akebia Therapeutics Inc stock priceInsider Buying Signals & Free Daily Market Summary and Trend Reports - earlytimes.in
Can Akebia Therapeutics Inc. (AX9) stock resist broad market declines2025 Major Catalysts & AI Powered Buy/Sell Recommendations - newser.com
How Akebia Therapeutics Inc. stock performs in interest rate cyclesProduct Launch & Daily Entry Point Alerts - newser.com
What to expect from Akebia Therapeutics Inc. in the next 30 days2025 Year in Review & Real-Time Stock Price Movement Reports - newser.com
How Akebia Therapeutics Inc. stock reacts to inflationary pressuresMarket Weekly Review & Low Drawdown Trading Techniques - newser.com
Should I hold or sell Akebia Therapeutics Inc. stock in 2025Trade Volume Summary & Advanced Technical Analysis Signals - newser.com
Published on: 2025-10-03 06:28:34 - newser.com
Is Akebia Therapeutics Inc. stock poised for growthRate Hike & Weekly High Conviction Ideas - newser.com
Will Akebia Therapeutics Inc. (AX9) stock profit from AI boom2025 Major Catalysts & Free Growth Oriented Trading Recommendations - newser.com
Leading vs lagging indicators on Akebia Therapeutics Inc. performanceJuly 2025 Sector Moves & Reliable Breakout Forecasts - newser.com
Why Akebia Therapeutics Inc. (AX9) stock is a strong buy callEarnings Recap Summary & Precise Trade Entry Recommendations - newser.com
Is Akebia Therapeutics Inc. stock entering bullish territoryJuly 2025 Technicals & Community Trade Idea Sharing Platform - newser.com
Is Akebia Therapeutics Inc. (AX9) stock attractive for dividend growthWeekly Trend Report & AI Based Trade Execution Alerts - newser.com
Why ETFs are accumulating Akebia Therapeutics Inc. (AX9) stockProfit Target & Fast Exit/Entry Strategy Plans - newser.com
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
204,163 Stock Options: Akebia Therapeutics Awards New Employee Grants with 4-Year Vesting Terms - Stock Titan
Published on: 2025-10-01 08:27:07 - newser.com
Why Akebia Therapeutics Inc. is moving todayTreasury Yields & High Accuracy Trade Signal Alerts - newser.com
How Akebia Therapeutics Inc. (AX9) stock moves in volatile trading sessions2025 Breakouts & Breakdowns & Safe Investment Capital Preservation Plans - newser.com
Published on: 2025-09-30 03:08:07 - newser.com
Atul Ltd (ATUL)’s Trend in 2025Head and Shoulders Patterns & Free Daily Investment Newsletter Subscription - earlytimes.in
Published on: 2025-09-28 22:31:40 - newser.com
Will Analyst Upgrades Continue to Fuel Sumeru Industries Limiteds RallyStock Buyback Updates & Free Triple Digit Wealth Increase - Early Times
Finanzdaten der Akebia Therapeutics Inc-Aktie (AKBA)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.54%
0.35%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):